Clinical Studies

Treatment of Joint Lameness and Osteoarthritis (OA) 

Osteoarthritis (OA) is considered one of the most important musculoskeletal disorders in both humans and horses. ^{1, 2} Clinically, it is associated with lameness and dysfunction of the affected joint and approximately 60% of all equine lameness is due to OA. ^{3, 4}It is characterised by breakdown and loss of joint cartilage, bony overgrowths (osteophytosis- seen on radiographs), (read more)

• Novel treatment for lameness.
• Treats underlying disease process.
• Positive effect on articular components.
• Reduces mechanoreceptor activation.
• Long lasting tissue compatibility.

Clinical Safety of Arthramid Vet 2.5% PAAG Hydrogel

Both in vitro and in vivo studies have taken place, designed to generate data on the safety of Arthramid Vet and to support regulatory submissions for market authorisation. Most current OA treatments are focused on reducing symptoms, and there are few effective treatments that address the underlying cause of the disease. (read more)

• Multiple Safety Studies.
• Neuro-innocuous.
• No adverse side effects.
• Widespread use in human medicine.
• Safe for competiton.

Arthramid Vet 2.5% PAAG – Mechanism Of Action

Arthritis describes inflammation of a joint and can happen after either a single or repetitive episodes of trauma. 31 The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis or OA. These pathological conditions are ‘a group of overlapping distinct diseases which may have different causes, but with similar biologic, anatomical, and clinical outcomes.’ (read more)

• Integrates into joint capsule.
• Restoring function to the joint.
• Increasing visco-elastic.
• Reduces pain & synovitis.
• Stable & non-absorbable.